Literature DB >> 33913094

MicroRNA-30c attenuates fibrosis progression and vascular dysfunction in systemic sclerosis model mice.

Yosuke Kanno1,2, En Shu3, Hirofumi Niwa3, Mariko Seishima3, Kei-Ichi Ozaki4.   

Abstract

Systemic sclerosis (SSc) is characterized by peripheral circulatory disturbance and fibrosis in skin and visceral organs. We recently demonstrated that α2-antiplasmin (α2AP) is elevated in SSc dermal fibroblasts and SSc model mice, and is associated with fibrosis progression and vascular dysfunction. In the present study, we predicted that α2AP could be a target of microRNA-30c (miR-30c) using TargetScan online database, and investigated the effect of miR-30c on the pathogenesis of SSc using a bleomycin-induced SSc model mice. miR-30c attenuated α2AP expression, and prevented the pro-fibrotic changes (increased dermal thickness, collagen deposition, myofibroblast accmulation) and the vascular dysfunction (the reduction of vascular endothelial cells (ECs) and blood flow) in the skin of SSc model mice. Furthermore, miR-30c suppressed pulmonary fibrosis progression in the SSc model mice. miR-30c exerts the anti-fibrotic and anti-angiopathy effects on SSc model mice, and might provide a basis for clinical strategies for SSc.

Entities:  

Keywords:  Alpha2-antiplasmin; Fibrosis; MiR-30c; Systemic sclerosis; Vascular dysfunction

Year:  2021        PMID: 33913094     DOI: 10.1007/s11033-021-06368-z

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  1 in total

1.  Decrease in matrix metalloproteinase‑3 activity in systemic sclerosis fibroblasts causes α2‑antiplasmin and extracellular matrix deposition, and contributes to fibrosis development.

Authors:  Hirofumi Niwa; Yosuke Kanno; En Shu; Mariko Seishima
Journal:  Mol Med Rep       Date:  2020-07-28       Impact factor: 2.952

  1 in total
  1 in total

Review 1.  α2-Antiplasmin as a Potential Therapeutic Target for Systemic Sclerosis.

Authors:  Yosuke Kanno; En Shu
Journal:  Life (Basel)       Date:  2022-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.